EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter phase II study of gemcitabine-oxaliplatin chemotherapy in untreated locally advanced or metastatic non-small cell lung cancer patients



Multicenter phase II study of gemcitabine-oxaliplatin chemotherapy in untreated locally advanced or metastatic non-small cell lung cancer patients



EJC Supplements 1(5): S238, September




(PDF 0-2 workdays service: $29.90)

Accession: 035349867

Download citation: RISBibTeXText



Related references

Phase I/II study of gemcitabine and oxaliplatin chemotherapy in combination with concurrent 3-D conformal radiotherapy for locally advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 9(4): 362-368, 2007

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). Cancer ChemoTherapy and Pharmacology 72(5): 1103-1110, 2013

Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Journal of Clinical Oncology 23(16_suppl): 7121-7121, 2016

Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Journal of Clinical Oncology 23(16_suppl): 7117-7117, 2016

Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 54(3): 347-352, 2006

Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study. Lung Cancer 40(1): 85-90, 2003

A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. Medical Oncology 32(4): 129-129, 2016

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Annals of Oncology 18(8): 1359-1362, 2007

A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab followed by bevacizumab alone in patients with locally advanced or metastatic non-small cell lung cancer (central localization excluded). Journal of Clinical Oncology 26(15_suppl): 19077-19077, 2016

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. Journal of Clinical Oncology 23(33): 8380-8388, 2005

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer ChemoTherapy and Pharmacology 73(4): 799-806, 2014

Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001. Anti-Cancer Drugs 19(5): 535-539, 2008

Preliminary results of a multicenter randomized phase II trial of two different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_suppl): 7124-7124, 2016

Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer. Journal of Clinical Oncology 23(27): 6664-6673, 2005

Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study. Strahlentherapie und Onkologie 182(5): 263-269, 2006